SAN DIEGO, Oct. 8, 2021 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM) today commented on a letter from leaders
in the House of Representatives to senior Biden Administration
officials calling for action to ensure coverage for the full range
of contraceptives under the Affordable Care Act (ACA).
"I want to take a moment to praise our leaders in Washington who are working to make sure women
have broad access to contraceptives, including new products like
Phexxi that have been approved by the FDA since the ACA's passage,"
said Saundra Pelletier, Chief
Executive Officer of Evofem. Phexxi® (lactic acid, citric acid
and potassium bitartrate), a hormone-free, on-demand
prescription contraceptive vaginal gel, was approved by the FDA in
May 2020.
"I would like to extend my gratitude to the authors of this
important letter: Energy and Commerce Chairman Frank Pallone, Jr. (D-NJ), Ways and Means
Chairman Richard E. Neal (D-MA),
Education and Labor Chairman Robert C. "Bobby" Scott (D-VA),
and Oversight and Reform Chairwoman Carolyn
B. Maloney (D-NY)," Pelletier added.
Leaders in the House of Representatives wrote to senior Biden
Administration officials — Health and Human Services Secretary
Xavier Becerra, Labor Secretary
Martin J. Walsh, and Treasury
Secretary Janet Yellen — requesting
that their Departments work together to ensure that the ACA's
requirements to provide individuals with coverage for the full
range of contraceptives approved by the Food and
Drug Administration (FDA) continue to be protected and
enforced.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing
innovative products to address unmet needs in women's sexual
and reproductive health, including hormone-free, woman-controlled
contraception and protection from certain sexually transmitted
infections (chlamydia and gonorrhea). The Company's first
FDA-approved product, Phexxi® (lactic acid, citric acid and
potassium bitartrate, is a hormone-free, on-demand
prescription contraceptive vaginal gel. It comes in a box of 12
pre-filled applicators and is applied 0-60 minutes before each act
of sex. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem
Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-commends-house-of-representatives-leaders-for-action-to-ensure-coverage-for-the-full-range-of-contraceptives-under-aca-301395947.html
SOURCE Evofem Biosciences, Inc.